Biologiske og molekylære effekter av hexaminolevulinate i blærekreft

Offentlig prosjektsammendrag

Changes in immune contexture has been evaluated as a possible therapeutic mechanism to support the long-term clinical efficacy seen after Hexvix blue light cystoscopy (BLC). The clinical impact of these immune modulatory effects, the synergistic effects with therapeutic drugs, or the role of Hexvix BLC in a therapeutic paradigm is currently unknown. The underlying molecular mechanisms will be further investigated to generate explanatory approaches at the molecular level, with the goal of evaluating a clinically relevant potential of the compound in a therapeutic approach. The project will utilize tissue from varying types of bladder cancer patients that has undergone different types of therapy with their outcomes registered, that in combination with advanced sequencing technology, can reveal insights into Hexvix BLC long-term benefits and new uses.